IN8bio, a Phase 1 biotech developing allogeneic T cell therapies for cancer and solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The company's pipeline contains lead candidates INB-200, which is currently in a Phase 1 trial for newly diagnosed glioblastoma, and INB-100, which is currently in a Phase 1 trial for patients with leukemia undergoing hematopoietic stem cell transplantation. Topline data is expected in 2021 and 2022, respectively.
The New York, NY-based company was founded in 2016 and plans to list on the Nasdaq under the symbol INAB. IN8bio filed confidentially on September 10, 2020. Barclays, Cantor Fitzgerald and Mizuho Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
